

BELLA WANG

Partner

Fangda Partners

+86 21 2208 5935

Bella.wang@fangdalaw.com



PRACTICE AREAS

MS. WANG SPECIALIZES IN GENERAL CORPORATE MATTERS AND IN COMMERCIAL LEGAL AFFAIRS, WITH EXTENSIVE PROJECT EXPERIENCE IN CROSS-BORDER AND DOMESTIC PRODUCT COLLABORATION, EARLY-STAGE R&D, LICENSING, MANUFACTURING, SUPPLY, AND COMMERCIALIZATION. SHE HAS A STRONG DEAL RECORD IN THE PHARMACEUTICAL, LIFE SCIENCE AND GENERAL INDUSTRY SECTORS.

REPRESENTATIVE MATTERS AND CASES

Licensing and Collaboration

- Represented JW Therapeutics (HKEX: 2126) in its collaboration with Juno Therapeutics (a wholly owned subsidiary of BMS) in granting Juno Therapeutics the global non-exclusive license for its proprietary sLVV manufacturing technology and related technologies for cell therapy product
- Represented Qyuns Therapeutics (2509.HK) in reaching a licensing and collaboration agreement with Caldera Therapeutics (co-founded by Lilly Asia Ventures, Atlas Venture and venBio) for the global right to exploit a long-acting bispecific QX030N treating autoimmune diseases
- Represented Nuvation Bio (NYSE: NUVB) in reaching a global non-exclusive API and product supply agreement with Asymchem (002821.SZ/6821.HK), a leading CDMO
- Represented Henlius (2696.HK) in licensing E-602 from Palleon Pharmaceuticals for the Greater China region and in reaching a global collaboration on combo therapy with Palleon Pharmaceuticals
- Represented Pfizer Investment in reaching an agreement with a leading pharmaceutical distributor to exclusively import and distribute two branded drugs in mainland China

- Represented Duality Bio (9606.HK) in granting commercialization rights to 3SBio's subsidiary Shenyang 3SBio for multiple indications of the DB-1303 product (a HER2 antibody-drug conjugate) in mainland China, Hong Kong, and Macau
- Represented TJ Bio in entering a strategic collaboration with Sanofi for developing, manufacturing and commercializing the globally innovative asset CD73 monoclonal antibody (Uliledlimab) in Greater China
- Represented CStone Pharmaceuticals (02616) in its strategic out-licensing partnership with Pharmalink (a pharmaceutical company headquartered in the United Arab Emirates) for commercialization of Sugemalimab (anti-PD-L1 mAb) in the Middle East and North Africa, and in its strategic out-licensing partnership with SteinCares (a leader in commercializing and distributing specialty healthcare products in Latin America) for commercialization of Sugemalimab (anti-PD-L1 mAb) in 10+ countries in Latin America
- Represented Kanghua (300841.SZ) in granting HilleVax (NASDAQ: HLVB) the exclusive right to develop, manufacture and commercialize Kanghua's hexavalent virus-like particle (VLP) norovirus vaccine candidate outside Greater China
- Represented CStone Pharmaceuticals in its strategic out-licensing partnership with Ewopharma for commercialization of Sugemalimab (anti-PD-L1 mAb) in Switzerland and nearly 20 other Central and Eastern European countries
- Represented Hengrui Pharmaceuticals (600276.SH/01276) in its out-licensing partnership with Aiolos Bio (subsequently acquired by GSK) with respect to the exploitation of Hengrui's innovative anti-TSLP monoclonal antibody (SHR-1905) outside Greater China
- Represented MingMed Biotech in its out-licensing partnership in Greater China with Elanco with respect to MingMed Biotech's small molecule drug for companion animals
- Represented Bao Pharmaceutical and its wholly-owned subsidiary Centergene Pharmaceuticals in entering a mainland China licensing agreement with Organon to exploit an innovative investigational asset in assisted reproductive technology (ART), SJ02, a long-acting FSH in BLA Process
- Represented CStone Pharmaceuticals in granting an exclusive commercial promotion right in mainland China to Allist for CStone Pharmaceuticals' approved RET inhibitor Gavreto® (Pralsetinib)
- Represented CStone Pharmaceuticals in its sale of the business and goodwill of Tibsovo® (including transferred assets) in Greater China and

Singapore to Servier, included negotiating, revising and executing an asset purchase agreement and a transitional services agreement

- Represented Junshi Biosciences (688180.SH/1877.HK) in obtaining an exclusive in-license from IAMA for the research, development, production, and commercialization of IAMA-001 inside Greater China, as well as for a collaboration outside Greater China
- Represented OADCT in out-licensing the distribution right to Zynlonta (CD19 targeted ADC drug for treating two types of B-cell lymphoma) to its partner in Southeast Asia
- Represented AstraZeneca in its granting exclusive commercialization rights to certain GLP-1 diabetes drugs in the PRC market to 3Sbio Inc (1530.HK)
- Represented AstraZeneca in obtaining exclusive rights from a leading Japan pharmaceutical company to commercialize in the PRC market certain drug products treating hyperkalemia
- Represented OnCusp Therapeutics in obtaining rights from Multitude Therapeutics to exploit AMT-707 (CDH6 targeted ADC drug) outside China
- Represented CStone Pharmaceuticals in out-licensing an exclusive commercialization right related to an anti-PD-1 monoclonal antibody (nofazinlimab) in mainland China to 3SBio Inc (1530.HK)
- Assisted CStone Pharmaceuticals on out-licensing CTLA-4 mAb's development and commercialization rights in Greater China to Hengrui Pharmaceuticals (600276.SH/01276)
- Represented Anheart Therapeutics in granting an exclusive commercialization right with respect to Anheart's lead drug candidate Taletrectinib to Innovent (01801.HK) in Greater China
- Represented Galixir in its collaboration on various transactions and R&D pipelines with other pharmaceutical companies utilizing AI technology in early-stage drug discovery and service provision
- Represented Syneron Bio in its collaboration with a multinational company on the utilization of AI technology in early-stage drug discovery and in R&D pipeline development
- Represented Junshi Biosciences (688180.SH/1877.HK) in its out-licensing to Zein Bio the exclusive commercialization rights in Greater China for its proprietary anti-PCSK9 antibody
- Represented AstraZeneca in granting to BioKangtai the exclusive license of AZD1222, an adenovirus vector-based COVID-19 vaccine
- Represented Tibet Rhodiola (known as Tibet Pharmaceuticals) in obtaining rights to Sputnik-V, an adenovirus vector-based COVID-19 vaccine from

Russia Direct Investment Fund (which belongs to the Russia National Wealth Fund)

- Represented Baxter and Cordis in their collaborations with Chinese partners developing, registering and manufacturing medical device products
- Represented multiple biopharmaceutical companies in their commissioned R&D collaborations with leading international and domestic CROs and CDMOs

Regulatory Matters

- Advised on the regulatory and compliance matters for pharmaceutical companies, biotech companies and medical device companies, including Pfizer, Biokin, Nuvation Bio, Qyuns Therapeutics, TJ Bio, Assembly Bio, Bristol Myers Squibb, AstraZeneca, Biogen, CStone Pharmaceuticals, Zai Lab, AnHeart Therapeutics, Virogin Biotech, VISEN Pharmaceuticals, Vyair Medical, Diurnal Group, Ionis Pharmaceuticals, UCB, GenEditBio, YST, Kangh, CMS, and Niumai

M&A and Investment

- Represented AstraZeneca in its USD 475 million investment in establishing a new small-molecule innovative drug manufacturing facility in Wuxi
- Represented a leading European dental equipment manufacturer in its joint venture with a leading Chinese dental company
- Represented Virogin Biotech in its series C, D1 and D2 financing
- Represented Sinopharm Capital and BVCF in their respective equity investments in biotech companies
- Represented Wacker in its acquisition of a majority interest in a PRC company and in its joint venture with a Chinese partner
- Represented Covestro in its proposed acquisition of a leading PRC manufacturer of thin films
- Represented E-Shang Redwood in its acquisitions and disposals of logistics assets in China
- Represented Redwood China Logistics Fund and others in selling top-tier logistics assets in mainland China to an entity established by ESR and Manulife Financial Group
- Represented LOGO Logistics in acquiring logistics property assets in China
- Represented Mount Kellett in its equity investment in and investment exit from a PRC real property brokerage company

OTHER INFORMATION

Education

- Boston University School of Law, LL.M. (2014)
- Shanghai University of Finance and Economics, School of Law, LL.B. and B.A. (Second Degree) (2011)

Professional Qualification

- Admitted to practice in PRC

Professional Background

Ms. Wang joined Fangda Partners as an associate in 2018. Before joining the firm, she worked for four years at a reputable red circle law firm and for over one year at a boutique law firm.